---
figid: PMC8862475__40170_2022_281_Fig7_HTML
figtitle: Combined inhibition of HMGCoA reductase and mitochondrial complex I induces
  tumor regression of BRAF inhibitor-resistant melanomas
organisms:
- NA
pmcid: PMC8862475
filename: 40170_2022_281_Fig7_HTML.jpg
figlink: /pmc/articles/PMC8862475/figure/Fig7/
number: F7
caption: Mechanistic features of synergy between IACS and STN. IACS treatment inhibits
  mitochondrial complex I and ATP generation by the electron transport chain (ETC),
  resulting in activation of AMPK, inhibition of mTOR, MAPK, and FA synthesis. IACS
  treatment also decreases acetyl CoA (Ac-CoA) uptake into FA synthesis, but increases
  its uptake into HMGCoA synthesis and activates mevalonate (MEV) pathway. This in
  turn activates RAS-mediated AKT. STN inhibits HMGCR, resulting in the inhibition
  of MEV pathway and AKT. Combination of IACS with STN starves inhibits FA-dependent
  BRAFV600E mutant melanoma cells by inhibition of FA and MEV pathways as well as
  MAPK and AKT pro-survival pathways
papertitle: Combined inhibition of HMGCoA reductase and mitochondrial complex I induces
  tumor regression of BRAF inhibitor-resistant melanomas.
reftext: Evelyn de Groot, et al. Cancer Metab. 2022;10:6.
year: '2022'
doi: 10.1186/s40170-022-00281-0
journal_title: Cancer & Metabolism
journal_nlm_ta: Cancer Metab
publisher_name: BioMed Central
keywords: Oxidative phosphorylation | Fatty acid metabolism | HMGCoA reductase | Statin
  | Melanoma | Therapeutic resistance
automl_pathway: 0.9558787
figid_alias: PMC8862475__F7
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8862475__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8862475__40170_2022_281_Fig7_HTML.html
  '@type': Dataset
  description: Mechanistic features of synergy between IACS and STN. IACS treatment
    inhibits mitochondrial complex I and ATP generation by the electron transport
    chain (ETC), resulting in activation of AMPK, inhibition of mTOR, MAPK, and FA
    synthesis. IACS treatment also decreases acetyl CoA (Ac-CoA) uptake into FA synthesis,
    but increases its uptake into HMGCoA synthesis and activates mevalonate (MEV)
    pathway. This in turn activates RAS-mediated AKT. STN inhibits HMGCR, resulting
    in the inhibition of MEV pathway and AKT. Combination of IACS with STN starves
    inhibits FA-dependent BRAFV600E mutant melanoma cells by inhibition of FA and
    MEV pathways as well as MAPK and AKT pro-survival pathways
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - stnA
  - stnB
  - l(1)16Fq
  - Coa
  - ras
  - Ras64B
  - Ras85D
  - gfr
  - nac
  - GluClalpha
  - betaGlu
  - pyr
  - sti
  - Raf
  - CycE
  - cyc
  - SNF4Agamma
  - AMPKalpha
  - Mtor
  - Tor
  - MKP-4
  - p38b
  - rl
  - Amph
  - ATPsynbeta
  - Atpalpha
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - EEF1A2
  - MSX2
  - ACY1
  - KRAS
  - HRAS
  - NRAS
  - RAPGEF5
  - CIT
  - DHDDS
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - MTOR
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - APRT
  - MFAP1
  - ATP8A2
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
---
